AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Pathophysiology of Hidradenitis Suppurativa

Description

The presentation discusses the complex pathophysiology of Hidradenitis Suppurativa (HS), emphasizing its distinct genetic and inflammatory characteristics compared to other skin conditions like psoriasis. It highlights the significance of recent genetic studies revealing that around 30% of HS cases have familial links and identifies specific genes associated with HS that differ from prior paradigms. The speaker notes that HS is primarily a folliculocentric disease driven by inflammation rather than simple follicular occlusion. Emerging understanding suggests a shift toward treating HS as an autoinflammatory condition, where systemic inflammation precedes follicular occlusion. The interplay of various immune cells, particularly the roles of fibroblasts, B cells, and T cells, is crucial in HS. Notably, the type of inflammation can vary significantly based on the disease morphology and individual comorbidities, complicating treatment responses. The talk also touches on the development of severe fibrotic complications in HS and the need for advanced therapeutic strategies targeting inflammation and fibrosis. Overall, it underscores the heterogeneous nature of HS and the ongoing need for innovative research to identify effective treatments.

View more

Conclusions

  • Hidradenitis Suppurativa (HS) is genetically complex, with about 30% of cases showing familial links.
  • Recent studies have identified significant genetic factors associated with HS, diverging from the previously held Notch signaling paradigm.
  • Inflammation in HS is marked by a heterogeneity involving multiple cell types, including T cells, B cells, fibroblasts, and distinct inflammatory markers.
  • The disease is characterized by a diverse inflammatory response influenced by systemic conditions like obesity and smoking.
  • The hair follicle is central to HS pathophysiology, with inflammation and occlusion in hair follicles contributing to disease progression.
  • Current understandings suggest that inflammation may lead to follicular occlusion rather than the other way around.
  • There is a need for nuanced therapeutic strategies aimed at the complex and heterogeneous nature of HS, moving away from one-size-fits-all approaches used in psoriasis.
  • Future research should focus on developing biomarkers that can predict treatment responses in HS patients for better individualized care.
  • Van Straalen et al. JAMA Dermatol. 2020.
  • Frew et al. Br J Dermatol. 2016; Frew et al. Front Immunol. 2021.
  • Sun et al. JAMA Dermatol. 2023.
  • Duchalet et al. JID 2020; Frew et al. Front Immunol 2021; Hessam et al. JEADV 2021.
  • Dunstan RW, et al. Histologic progression of acne inversa/hidradenitis suppurativa: Implications for future investigations and therapeutic intervention. Exp Dermatol. 2021.
  • van Straalen KR, et al. Single cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa. J Clin Invest (2023).
  • Moran et al. Targeting the NLRP3 inflammasome reduces inflammation in hidradenitis suppurativa skin, British Journal of Dermatology (2023).
  • Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol. 2021 Jun;147(6):2213-2224.
  • Frew et al. JAMA Dermatol. 2021;157(4):449-455. doi:10.1001/jamadermatol.2020.5467.
  • Byrd et al. Sci Trans Med 2019.
  • Rebecca Jepsen, RN, Chloe Edwards, RN, Akshay Flora, MD, MMed, MRes, Emily Kozera, BMedSc, MD, MPH, MBeth, John W. Frew, MBBS, MMed, MS, PhD. Journal of the American Academy of Dermatology Volume 89 Issue 4 Pages 694-702 (October 2023).
  • Flora et al. PLoS One 2023.
  • Van Straalen et al. 2023, Flora et al. 2023.